What can go wrong with unapproved stem cell clinic offerings? The answer including from presentations at the FDA today turns out to be very serious, negative results right here in the U.S. Thomas Albini, MD gave a talk entitled, “Severe Visual Loss After Intravitreal Injection of Autologous Adipose Tissue-derived Stem Cells for Age-related Macular Degeneration”. […]
Negative stem cell clinic outcomes include 3 blinded women Read More »
Here is a hub for 2017 stem cell and regenerative medicine meetings. If you do not see your meeting, please let me know and I will include it. Change– I’m also going to be listing online courses (in red) this year. This list is meant to be as inclusive as possible, but by listing specific
Stem Cell Meetings & Conferences 2017 Read More »
The FDA continues to be very active with warning letters against makers of stem cell cosmetics even as it has been relatively dormant on stem cell clinics. You can read past posts on the long series of warning letters to manufacturers of stem cell cosmetic cream. Three new warning letters to stem cell cream makers
3 more FDA warning letters to stem cell cosmetics makers Read More »
Last week a team led by John Rasko of the University of Sydney published a very important stem cell clinic study also in Cell Stem Cell. Thus, there have now been two new reports on the state of the stem cell clinic industry both here in the U.S. and more globally. Leigh Turner and I published
Important Rasko team paper on global distribution of stem cell clinics Read More »
When potentially game changing new technologies are reported such as NgAgo gene editing, both scientists and the public get excited, but especially if such new reports stem from a single paper it is wise to take a cautious approach for a while. The key question is whether the new findings will turn out to be
Nature Biotechnology looking at NgAgo paper amidst reproducibility concerns Read More »
By Gaetan Burgio CRISPR/Cas9 genome editing has dramatically changed our way to perform biological experiments. While highly efficient and easy to use, one limitation with CRISPR/Cas9 mediated genome editing technology is the occurrence of off-target effects and the restriction of the PAM recognition sequence. Many modifications from the original system have been proposed to improve
Gaetan Burgio New Data & Theory on NgAgo versus CRISPR Read More »
Does the new gene editing method NgAgo work or not? If not, what happened? The answers to both questions seem to depend on who you ask and what you read. As much as CRISPR has been the revolutionary in the genetic modification technology arena over past methods, could CRISPR itself in the next few years
Controversy over CRISPR challenger NgAgo irreproducibility reported Read More »
Each December I make stem cell predictions for the coming year and I did that for 2016 where I made 20 predictions. At around mid year I do a checkup on how my predictions are doing halfway and that is the purpose of this post. Below are my predictions that I made in 2015 for stem
Stem cell checkup: how are my 2016 predictions doing half way? Read More »
A committee of the International Society for Stem Cell Research (ISSCR) did one heck of a document dump yesterday on stem cell policy, releasing a whole bunch of policy recommendations on stem cells and more. The torrent from ISSCR included a 37-page policy statement itself as well as several papers in top journals including the
ISSCR Releases Flood of Stem Cell Policy Docs Read More »
Editor’s note. Caroline Simons attended both the April 28th (see her report on that here) and 29th Paris meetings on human gene editing/genetic modification. Today, we have her in depth report on the April 29th meeting. I have posted her piece in full with only minor edits. If you are in a rush you can
In Depth Report from April 29th Paris Human Gene Editing Meeting Read More »